POLE and neoplasm: Given the overlap of POLE and MMR mutations in published data and our reported cases, we acknowledge the possibility that our six samples with high tumor mutational burden may classify into either POLE ultra-mutated or MSI hypermutated subgroups with additional supporting data not measured by next generation sequencing.